US2017190784A1PendingUtilityA1

Activin-actriia antagonists and uses for treating multiple myeloma

57
Assignee: ACCELERON PHARMA INCPriority: Nov 23, 2005Filed: Jan 11, 2017Published: Jul 6, 2017
Est. expiryNov 23, 2025(expired)· nominal 20-yr term from priority
Inventors:John KnopfJasbir SeehraRavindra Kumar
A61P 35/00A61P 43/00A61P 5/18A61P 35/04A61P 5/14A61P 21/00A61P 19/00A61P 13/12A61P 19/08A61P 19/10A61K 38/1796C07K 2317/21C07K 2319/02C07K 14/4702C07K 2317/622C07K 19/00A61K 38/18C07K 2317/24A61K 39/39558C07K 2317/55C07K 14/71C07K 2317/54C07K 16/3061C07K 2317/31A61K 2039/505C07K 2319/30A61K 38/179A61K 45/06H04W 80/04H04W 8/082H04W 84/18H04L 2212/00H04W 40/00
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.

Claims

exact text as granted — not AI-modified
1 - 65 . (canceled) 
     
     
         66 . A method for treating or preventing multiple myeloma in a human patient, the method comprising administering to the patient an effective amount of an anti-activin antibody or fragment thereof. 
     
     
         67 . The method of  claim 66 , wherein the antibody or fragment thereof is a chimeric antibody. 
     
     
         68 . The method of  claim 66 , wherein the antibody or fragment thereof is a humanized antibody. 
     
     
         69 . The method of  claim 66 , wherein the antibody or fragment thereof is a human antibody. 
     
     
         70 . The method of  claim 66 , wherein the antibody or fragment thereof is a monoclonal antibody. 
     
     
         71 . The method of  claim 66 , wherein the antibody or fragment thereof is an F(ab) 2  fragment. 
     
     
         72 . The method of  claim 66 , wherein the antibody or fragment thereof is an Fab fragment. 
     
     
         73 . The method of  claim 66 , wherein the antibody or fragment thereof is a single chain antibody. 
     
     
         74 . The method of  claim 66 , wherein the antibody or fragment thereof is a bi-specific antibody. 
     
     
         75 . The method of  claim 66 , wherein the antibody or fragment thereof further comprises one or more agents selected from: a radioisotope, a fluorescent compound, and an enzyme or enzyme co-factor. 
     
     
         76 . The method of  claim 66 , wherein the antibody or fragment thereof binds to activin A. 
     
     
         77 . The method of  claim 66 , wherein the antibody or fragment thereof binds to activin B. 
     
     
         78 . The method of  claim 66 , wherein the antibody or fragment thereof binds to activin A and B. 
     
     
         79 . The method of  claim 66 , wherein the antibody or fragment thereof inhibits activin from binding to ActRIIa. 
     
     
         80 . The method of  claim 66 , wherein the antibody or fragment thereof reduces tumor burden in the patient. 
     
     
         81 . The method of  claim 66 , wherein the antibody or fragment thereof treats or prevents bone loss in the patient. 
     
     
         82 . The method of  claim 66 , wherein the antibody or fragment thereof is administered to the patient in combination with one or more bone-active agents selected from: a calcium supplement, vitamin D, a bisphosphonate, calcitonin, estrogen, parathyroid hormone, and raloxifene.

Join the waitlist — get patent alerts

Track US2017190784A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.